Liraglutide vs Semaglutide: Is Saxenda Still Worth Considering in 2026?

Liraglutide was the first GLP-1 receptor agonist approved for chronic weight management. When Saxenda received FDA approval in 2014, it represented a genuine advance—the first injectable medication in years to demonstrate meaningful, sustained weight loss in a randomized controlled trial population. For a decade, it held a central place in obesity pharmacotherapy. Then semaglutide arrived, and the clinical question became unavoidable: is there still a case for liraglutide?

The Pharmacological Difference

Both liraglutide and semaglutide are GLP-1 receptor agonists, but they differ in ways that matter clinically. Liraglutide has a half-life of approximately 13 hours, which is why it requires daily injection. Semaglutide’s half-life is approximately 7 days, enabling once-weekly dosing. This is not merely a convenience difference—it affects the steady-state receptor exposure, which in turn affects efficacy.

Semaglutide also has higher GLP-1 receptor binding affinity than liraglutide. The combined effect of greater affinity and longer duration of action produces more consistent receptor activation over the dosing interval, which is reflected in the efficacy data.

The Trial Data, Directly Compared

The SCALE trials established liraglutide’s efficacy in obesity. SCALE Obesity and Prediabetes (n=3,731, 56 weeks) found mean weight loss of 8.0% vs 2.6% placebo. The STEP trials established semaglutide 2.4 mg’s efficacy. STEP-1 (n=1,961, 68 weeks) found mean weight loss of 14.9% vs 2.4% placebo.

These trials enrolled different populations under different conditions and cannot be compared as if they were head-to-head. But the magnitude of difference—nearly twice the weight loss with semaglutide—is consistent with mechanistic predictions and is reflected in clinical practice observations. STEP-8 subsequently conducted a head-to-head comparison of semaglutide 2.4 mg versus liraglutide 3.0 mg in adults with overweight or obesity (n=338, 68 weeks). The results were unambiguous: semaglutide produced mean weight loss of 15.8% compared to 6.4% for liraglutide, with 70.9% of semaglutide participants losing at least 10% of body weight versus 25.6% on liraglutide.

The discontinuation data deserves attention: liraglutide was discontinued for adverse events at nearly four times the rate of semaglutide in the same trial. This is consistent with clinical experience, where daily injection and more pronounced gastrointestinal side effects with liraglutide produce adherence challenges that blunt real-world outcomes relative to trial conditions.

Is There Still a Clinical Case for Liraglutide?

The efficacy comparison is not close. By every primary and secondary endpoint in STEP-8, semaglutide was substantially more effective than liraglutide with better tolerability. The logical question is whether there are clinical circumstances in which liraglutide is still a reasonable choice.

Insurance coverage as a deciding factor

Some commercial insurance plans have liraglutide (Saxenda) on their formulary but do not yet cover semaglutide 2.4 mg (Wegovy). In that specific situation, a covered prescription for Saxenda may be more accessible than paying out-of-pocket for Wegovy—at least until the patient can navigate the prior authorization process for a higher-efficacy option or coverage changes at renewal.

Patients who cannot tolerate weekly injections

A small subset of patients experience injection site reactions or significant anxiety with any injection and prefer the smaller daily volume of liraglutide pens over weekly doses. The clinical rationale here is thin—both require regular injection, and the tolerability data favors semaglutide—but patient-specific factors including needle anxiety and injection volume preference sometimes influence real-world prescribing.

Transitional use

Liraglutide is occasionally used as an initial step in patients for whom a physician wants to assess GLP-1 tolerance before committing to a longer-acting agent. The pharmacological logic is limited (daily liraglutide does not predict weekly semaglutide tolerance in a way that changes management), but it occasionally appears in practice as a conservative approach.

Cost and Access

Saxenda’s retail list price is approximately $1,349 per month, nearly identical to Wegovy. Compounded liraglutide is not available in the same way that compounded semaglutide has been, because liraglutide was not on FDA’s shortage list. Cash-pay access to liraglutide therefore primarily involves the brand-name product with or without a manufacturer savings program.

Given the substantially inferior efficacy and similar cost, the case for choosing Saxenda over Wegovy or a semaglutide telehealth program on cost grounds is weak. The primary scenario in which liraglutide remains a practical choice is when insurance coverage exists specifically for it but not for semaglutide—and even then, the appropriate clinical response is to use it while pursuing coverage or access for a higher-efficacy agent.